Emerald Bioscience Inc. (OTCMKTS:EMBI – Get Free Report)’s share price rose 3.4% on Wednesday . The company traded as high as $0.7034 and last traded at $0.6933. 73,291 shares were traded during mid-day trading, a decline of 99% from the average session volume of 14,236,620 shares. The stock had previously closed at $0.6705.
Emerald Bioscience Stock Down 2.6%
The stock has a fifty day simple moving average of $0.79. The firm has a market capitalization of $181.00 million, a PE ratio of -8.44 and a beta of 0.43. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.43.
Emerald Bioscience Company Profile
Emerald Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus.
See Also
- Five stocks we like better than Emerald Bioscience
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
- Why Kroger’s Giant Eagle Deal Could Change Everything
Receive News & Ratings for Emerald Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emerald Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
